Navigation Links
InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
Date:2/13/2009

BRISBANE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock. The last reported sale price of InterMune's common stock on the NASDAQ Global Select Market on February 12, 2009 was $17.96. The offering is expected to close on or about February 19, 2009, subject to customary closing conditions. All of the shares are being sold by the company.

UBS Investment Bank is the sole manager for the offering. InterMune has granted the underwriter a 30-day option to purchase up to an additional 525,000 shares to cover over-allotments, if any.

A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission.

A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement and the accompanying prospectus may be obtained from

                                 UBS Investment Bank
                             ATTN: Prospectus Department
                                   299 Park Avenue
                                  New York, NY 10171
                       or by telephone toll free at 888-827-7275.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of InterMune's common stock, nor shall there be any sale of such common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About InterMune

InterMune is a biotechnology company focused on the research,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... are continually reaching new lows as they reduce the temperatures ... low enough to overcome the entropy (a measure of the ... discovery of exotic states of ultra-cold matter. Now physicists at ... out of a collection of atoms in much the same ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ... Hardev Pandha of the Royal Surrey County Hospital, U.K., ... of Clinical Cancer Research. The paper is entitled "Synergistic ... Malignant Melanoma." , The research demonstrated that the innate ...
... , CAMBRIDGE, Mass., Sept. 24 Peptimmune, Inc. ... has formed a research and development collaboration with the Walter ... Research Center (NMRC), Silver Spring, MD to evaluate the Company,s ... dengue vaccines and point-of-care diagnostics. , , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial 2Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities 2
(Date:8/19/2014)... UK 19 August 2014: An engineer at the ... despite not having a brain to communicate with the ... Harvard, Professor L Mahadevan, has developed a mathematical model ... view of how these soft bodied animals get around. ... the central pattern generator (CPG) which states that the ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... exist in different forms, they have not been widely ... Now researchers from the University of Surrey and Trinity ... elastic bands with graphene, to create a flexible sensor ... be made cheaply. , Once treated, the rubber ... graphene - which imparts an electromechanical response on movement ...
Breaking Biology News(10 mins):Secrets of how worms wriggle uncovered 2
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
... bugs, according to Gilbert Waldbauer, whose book "Insights From Insects: ... (Prometheus Books). , "We know a lot about pests, because ... professor emeritus of entomology at the University of Illinois at ... 2 percent are considered pests. Just as some plants growing ...
... synthesis of QS-21A, a medicinally important molecule that helps ... at the University of Illinois at Urbana-Champaign. , In ... the body's immune response in vaccine therapies against aggressive ... prostate cancer, HIV-1 and malaria. An extract from the ...
Cached Biology News:Virologists make major step towards understanding the process of HIV infection 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: